Edwards Lifesciences acquires Israeli Valtech Cardio for 990$ million
28 November, 2016
Valtech's Cardioband received CE Mark certification in September 2015. Edwards will pay a whooping 990$ million for the Israeli med-tech company
Valtech’s Cardioband received CE Mark certification in September 2015. Edwards will pay a whooping 990$ million for the Israeli med-tech company
Israeli Valtech Cardio, an innovator in the field of device development for mitral and tricuspid valve repair and replacement, announced agreement to be acquired by Edwards Lifesciences Corporation (Edwards). The acquisition will give Edwards access to the Cardioband Reconstruction System (Cardioband) for transcatheter repair of the mitral valve and tricuspid valve of the heart.
“We are pleased that Edwards, a global leader in patient focused medical innovations for structural heart disease, has elected to include in its growing portfolio of transcatheter based therapies, the Cardioband system for both mitral and tricuspid valve repair. We believe this will position CardiobandTM to achieve its full potential as a fundamental breakthrough in the way patients are treated for both mitral and tricuspid regurgitation” said Amir Gross, Founder and CEO of Valtech. “On behalf of the entire Valtech organization, I want to thank the many physicians who supported us over the past ten years in the development of the Cardioband platform.”
“None of our success with the Cardioband program could have been achieved without the passion and perseverance of the entire Valtech team. We are extremely proud of their accomplishments over the past ten years, and are very excited about the potential impact CardiobandTM will have on patient care in the years ahead,” said Lawrence Best, Executive Chairman of Valtech.